Clinical Trials in Hungary

• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 Phase III Metastatic Castration-Resistant Prostate Cancer Merck Sharp & Dohme LLC
• A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi… Ended
  2024-511972-33-00 Phase III Primary myelofibrosis, post-polycythemia vera myelofibrosis … Celgene Corp.
• Phase 3b/4 Study in Rheumatoid Arthritis Ended
  2023-508022-10-00 Phase IV Rheumatoid Arthritis Eli Lilly & Co.
• Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Ended
  2023-504928-26-00 Phase III Chronic Migraine Amgen Inc.
• Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy Ended
  2022-501439-18-00 Phase III NSCLC with squamous or nonsquamous histology Merck Sharp & Dohme LLC
• Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended
  2022-500413-11-00 Phase III Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) Merck Sharp & Dohme Corp.
• A study to assess different investigational drugs for the treatment if hidradenitis suppurativa Ended
  2023-509296-16-00 Phase II Moderate to severe hidradenitis suppurativa Novartis Pharma AG
• A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli… Ended
  2022-501970-20-01 Phase III Cis-eligible Muscle-invasive bladder cancer. Merck Sharp & Dohme LLC
• A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specifi… Ended
  2024-511798-31-00 Phase I (FiH) KRAS p.G12C Mutant Advanced Solid Tumors Amgen Inc.
• Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus Ended
  2022-502444-13-00 Phase II Systemic Lupus Erythematosus Bristol Myers Squibb International Corporation
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 Phase III Adults at high risk of cardiovascular events without prior M… Amgen Inc.
• Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su… Ended
  2022-501971-24-00 Phase III Adjuvant treatment of HCC Merck Sharp & Dohme LLC
• A study evaluating the efficacy and safety of ralinepag in treatment of patients with pulmonary arterial hypertension. Ended
  2023-509304-16-00 Phase III Pulmonary arterial hypertension (PAH) United Therapeutics Corp.
• Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality Ended
  2022-502187-20-00 Phase III Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a det… Instituto Grifols S.A.
• A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis. Ended
  2023-505476-29-00 Phase III Giant Cell Arteritis AbbVie Deutschland GmbH & Co. KG
• MK-4280 and Pembrolizumab in Hematologic Malignancies Ended
  2023-503587-17-00 Phase I/II Hematologic malignancies Merck Sharp & Dohme LLC
• Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended
  2022-500395-57-00 Phase III Resectable high-risk Locally Advanced Cutaneous Squamous Cel… Merck Sharp & Dohme Corp.
• This is a phase III randomised, double-blind, placebo-controlled, multicentre, global study to assess the effectiveness and safety of standa… Ended
  2022-502747-35-00 Phase III Newly diagnosed advanced (FIGO stage III-IV) high grade epit… AstraZeneca AB
• A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Su… Ended
  2023-506687-13-00 Phase III Primary Generalized Tonic-Clonic Seizures Sk Life Science Inc.
• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended
  2022-502936-38-00 Phase III Moderate and Severe Atopic Dermatitis Abbvie Deutschland GmbH & Co. KG
• First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended
  2022-502124-52-00 Phase III Advanced epithelial ovarian cancer Merck Sharp & Dohme LLC
• A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effectiv… Ended
  2023-508955-37-00 Phase III Moderate to severe atopic dermatitis Pfizer Inc.
• Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended
  2024-511553-22-00 Phase III Moderately to Severely Active Crohn's Disease Celgene International II SARL
• Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease Ended
  2023-510426-33-00 Phase III Moderately to Severely Active Crohn's Disease Celgene International II S.a.r.l.

Showing 1,201–1,224 of 1,255 trials